Nu-derm System Normal-dry Skin Transformation Trial

Hydroquinone, Homosalate, Octisalate, And Zinc Oxide


Obagi Cosmeceutical Llc
Human Prescription Drug
NDC 62032-532
Nu-derm System Normal-dry Skin Transformation Trial also known as Hydroquinone, Homosalate, Octisalate, And Zinc Oxide is a human prescription drug labeled by 'Obagi Cosmeceutical Llc'. National Drug Code (NDC) number for Nu-derm System Normal-dry Skin Transformation Trial is 62032-532. This drug is available in dosage form of Kit. The names of the active, medicinal ingredients in Nu-derm System Normal-dry Skin Transformation Trial drug includes . The currest status of Nu-derm System Normal-dry Skin Transformation Trial drug is Active.

Drug Information:

Drug NDC: 62032-532
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Nu-derm System Normal-dry Skin Transformation Trial
Also known as the trade name. It is the name of the product chosen by the labeler.
Proprietary Name Base: Nu-derm System Normal-dry
The base of the Brand/Proprietary name excluding its suffix.
Proprietary Name Suffix: SKIN TRANSFORMATION TRIAL
A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Hydroquinone, Homosalate, Octisalate, And Zinc Oxide
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Obagi Cosmeceutical Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Kit
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 02 Dec, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 01 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:OBAGI COSMECEUTICAL LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:197795
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
62032-532-071 KIT in 1 CARTON (62032-532-07) * 59 mL in 1 BOTTLE, PLASTIC * 28 g in 1 BOTTLE, PLASTIC * 57 g in 1 BOTTLE, PLASTIC * 28 g in 1 BOTTLE, PLASTIC * 59 mL in 1 BOTTLE, PLASTIC * 85 g in 1 TUBE02 Dec, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Active ingredients purpose homosalate 10% sunscreen octisalate 5% sunscreen zinc oxide 16.5% sunscreen

Product Elements:

Nu-derm system normal-dry skin transformation trial hydroquinone, homosalate, octisalate, and zinc oxide nu-derm toner water glycerin hamamelis virginiana top water sodium pyrrolidone carboxylate dmdm hydantoin iodopropynyl butylcarbamate potassium alum panthenol sage calendula officinalis flower polysorbate 80 allantoin aloe vera leaf fd&c blue no. 1 nu-derm gentle cleanser water glycerin phenoxyethanol methylparaben propylparaben butylparaben ethylparaben isobutylparaben carbomer interpolymer type a (allyl sucrose crosslinked) sodium lauroyl oat amino acids cocamidopropyl betaine sodium laureth-3 sulfate aloe vera leaf glycereth-7 panthenol diethylene glycol monoethyl ether trolamine sage fd&c yellow no. 5 apricot kernel oil oleyl lactate nu-derm clear skin bleaching and corrector hydroquinone hydroquinone hydroquinone edetate disodium butylparaben stearyl alcohol sodium lauryl sulfate cetyl alcohol glycerin lactic acid, unspecified form .alpha.-tocopherol acetate ascorbic acid sodium metabisulfite water methylparaben propylparaben butylated hydroxytoluene nu-derm exfoderm skin smoothing water glycerin methylparaben propylparaben polysorbate 60 cetostearyl alcohol steareth-20 canola oil isohexadecane magnesium aluminum silicate cetyl alcohol fytic acid glyceryl monostearate peg-100 stearate dimethicone peg-150 stearate phenoxyethanol butylparaben ethylparaben isobutylparaben potassium cetyl phosphate xanthan gum .alpha.-tocopherol acetate glycereth-7 diethylene glycol monoethyl ether bis-diglyceryl polyacyladipate-2 sodium hydroxide nu-derm blender skin lightener and blending hydroquinone hydroquinone hydroquinone edetate disodium ppg-2 myristyl ether propionate trolamine salicylate sodium lauryl sulfate cetyl alcohol glycerin lactic acid, unspecified form .alpha.-tocopherol acetate ascorbic acid sodium metabisulfite water methylparaben propylparaben butylated hydroxytoluene phenyl trimethicone nu-derm sun shield broad spectrum spf 50 matte sunscreen homosalate, octisalate, and zinc oxide homosalate homosalate octisalate octisalate zinc oxide zinc oxide water glycerin hydroxyacetophenone xanthan gum sodium chloride sodium hydroxide octyldodecyl neopentanoate triethoxycaprylylsilane c15-19 alkane disteardimonium hectorite polyglyceryl-2 isostearate sorbitan olivate dimethicone 1,2-hexanediol caprylyl glycol edetate disodium candelilla wax yellow wax polymethylsilsesquioxane (4.5 microns) silicon dioxide

Indications and Usage:

Indications and usage for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines and other unwanted areas of melanin hyperpigmentation.

Uses helps prevent sunburn if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun

Warnings:

Warnings hydroquinone is a skin-bleaching agent, which may produce unwanted cosmetic effects if not used as directed. the physician should be familiar with the contents of this insert before prescribing or dispensing this product. test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check within 24 hours. some users of this product may experience a mild skin irritation. if skin irritation becomes severe, stop use and consult a doctor. close patient supervision is recommended. warnings: avoid contact with eyes, nose, mouth and lips. in case of accidental contact, patient should rinse thoroughly with water and contact a physician. sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity. contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain suscepti
ble people. the overall prevalence of sulfite sensitivity in the general population is unknown and probably low. sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Warnings: avoid contact with eyes, nose, mouth and lips. in case of accidental contact, patient should rinse thoroughly with water and contact a physician. sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity. contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. the overall prevalence of sulfite sensitivity in the general population is unknown and probably low. sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Warnings for external use only do not use on damaged or broken skin stop use and ask a doctor if rash occurs when using this product keep out of eyes. rinse with water to remove. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

Do Not Use:

Warnings hydroquinone is a skin-bleaching agent, which may produce unwanted cosmetic effects if not used as directed. the physician should be familiar with the contents of this insert before prescribing or dispensing this product. test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check within 24 hours. some users of this product may experience a mild skin irritation. if skin irritation becomes severe, stop use and consult a doctor. close patient supervision is recommended. warnings: avoid contact with eyes, nose, mouth and lips. in case of accidental contact, patient should rinse thoroughly with water and contact a physician. sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity. contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. the overall prevalence of sulfite sensitivity in the general population is unknown and probably low. sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Warnings: avoid contact with eyes, nose, mouth and lips. in case of accidental contact, patient should rinse thoroughly with water and contact a physician. sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity. contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. the overall prevalence of sulfite sensitivity in the general population is unknown and probably low. sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Warnings for external use only do not use on damaged or broken skin stop use and ask a doctor if rash occurs when using this product keep out of eyes. rinse with water to remove. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

When Using:

When using this product keep out of eyes. rinse with water to remove.

Dosage and Administration:

Dosage and administration a thin application should be applied once or twice daily or as directed by a physician. if no improvement is seen after three (3) months of treatment, use of this product should be discontinued. sun exposure should be limited by using a sunscreen agent or protective clothing to cover bleached skin when using and after using this product in order to prevent darkening from reoccurring.

Directions apply liberally 15 minutes before sun exposure use a water resistant sunscreen if swimming or sweating reapply at least every 2 hours sun protection measures. spending time in the sun increases your risk of skin cancer and early skin aging. to decrease this risk, regularly use a sunscreen with a broad spectrum spf value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m.–2 p.m. wear long-sleeved shirts, pants, hats, and sunglasses children under 6 months: ask a doctor

Stop Use:

Stop use and ask a doctor if rash occurs

Contraindications:

Contraindications people with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. the safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

Adverse Reactions:

Adverse reactions no systemic adverse reactions have been reported. occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and the physician notified immediately. to report suspected adverse reactions, contact obagi cosmeceuticals llc, at 1-800-636-7546 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Use in Pregnancy:

Pregnancy category c animal reproduction studies have not been conducted with topical hydroquinone. it is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. it is not known to what degree, if any, topical hydroquinone is absorbed systemically. topical hydroquinone should be used on pregnant women only when clearly indicated.

Pediatric Use:

Pediatric usage safety and effectiveness in children below the age of 12 years have not been established.

Description:

Description hydroquinone, usp 4% is 1, 4-benzenediol. the drug is freely soluble in water and in alcohol. chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is c 6 h 6 o 2 ; molecular weight is 110.11 g/mol. the chemical structure is in the diagram below. c 6 h 6 o 2 chemical structure each gram of obagi nu-derm ® clear contains: active: hydroquinone, usp 4% (40 mg/g) inactives: ascorbic acid, bht, butylparaben, cetyl alcohol, disodium edta, glycerin, lactic acid, methylparaben, propylparaben, saponins, sodium lauryl sulfate, sodium metabisulfite, stearyl alcohol, tocopheryl acetate, water (aqua) each gram of obagi nu-derm blender ® contains: active: hydroquinone, usp 4% (40 mg/g) inactives: ascorbic acid, bht, cetyl alcohol, disodium edta, glycerin, lactic acid, methylparaben, phenyl trimethicone, ppg-2 myristyl ether propionate, propylparaben, saponins, sodium lauryl sulfate, sodium metabisulfite, tea-salicylate, tocopheryl acetate, water (aqua) each gram of obagi nu-derm ® sunfader ® contains: actives: hydroquinone, usp 4% (40mg/g); octinoxate, usp 7.5%; oxybenzone, usp 5.5% inactives: ascorbic acid, bht, butylparaben, cetyl alcohol, disodium edta, glycerin, methylparaben, propylparaben, saponins, sodium lauryl sulfate, sodium metabisulfite, stearyl alcohol, tocopheryl acetate, water (aqua)

Clinical Pharmacology:

Clinical pharmacology topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (dopa) and suppression of other melanocyte metabolic processes. exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunscreen agents such as those contained in obagi nu-derm sunfader ® and obagi nu-derm ® sun shield matte broad spectrum spf 50.

How Supplied:

How supplied obagi nu-derm ® clear is available as follows: net wt. 2 oz. (57 g) bottle ndc 62032-101-36 obagi nu-derm blender ® is available as follows: net wt. 2 oz. (57 g) bottle ndc 62032-100-36 net wt. 1 oz. (28 g) bottle ndc 62032-100-10 obagi nu-derm sunfader ® is available as follows: net wt. 2 oz. (57 g) bottle ndc 62032-116-36 store at controlled room temperature: 15° to 25°c (59° to 77°f). keep out of direct sunlight.

Package Label Principal Display Panel:

Principal display panel - kit carton ndc# 62032-532-07 obagi ® medical obagi nu-derm ® system normal dry skin transformation trial kit principal display panel - kit carton

Further Questions:

Questions or comments? 1.800.636.7546 monday–friday 9 a.m.–4 p.m. pacific time


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.